These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 11220515)

  • 1. In-vivo and in-vitro models of type 2 diabetes in pharmaceutical drug discovery.
    Reed MJ; Scribner KA
    Diabetes Obes Metab; 1999 Mar; 1(2):75-86. PubMed ID: 11220515
    [No Abstract]   [Full Text] [Related]  

  • 2. American Diabetes Association--69th Scientific sessions. Hyperinsulinism, insulin resistance and the treatment of diabetes: Part 2.
    Kouremenou C
    IDrugs; 2009 Aug; 12(8):465-6. PubMed ID: 19629874
    [No Abstract]   [Full Text] [Related]  

  • 3. American Diabetes Association--69th Scientific sessions. Obesity management and treatment of type 2 diabetes: Part 1.
    Kouremenou C
    IDrugs; 2009 Aug; 12(8):463-4. PubMed ID: 19629873
    [No Abstract]   [Full Text] [Related]  

  • 4. European Association for the Study of Diabetes--43rd Annual Meeting. Therapeutic approaches: Part 2. 18-21 September 2007, Amsterdam, the Netherlands.
    Toft AD
    IDrugs; 2007 Nov; 10(11):769-71. PubMed ID: 17968754
    [No Abstract]   [Full Text] [Related]  

  • 5. Progress in the treatment of type 2 diabetes: new pharmacologic approaches to improve glycemic control.
    Cohen A; Horton ES
    Curr Med Res Opin; 2007 Apr; 23(4):905-17. PubMed ID: 17407648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. From anatomy to the target: contributions of magnetic resonance imaging to preclinical pharmaceutical research.
    Beckmann N; Mueggler T; Allegrini PR; Laurent D; Rudin M
    Anat Rec; 2001 Apr; 265(2):85-100. PubMed ID: 11323771
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mouse models of type II diabetes mellitus in drug discovery.
    Baribault H
    Methods Mol Biol; 2010; 602():135-55. PubMed ID: 20012397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Research progress of the drug screening technology in type 2 diabetes mellitus].
    Luo A; Fan Y; Luo A; Song G
    Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2006 Aug; 23(4):895-8. PubMed ID: 17002133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [New outlooks in the treatment of diabetes].
    Salamanca-Gómez F
    Gac Med Mex; 1999; 135(4):441-2. PubMed ID: 10491904
    [No Abstract]   [Full Text] [Related]  

  • 10. Genetically engineered mice in drug development.
    Livingston JN
    J Intern Med; 1999 Jun; 245(6):627-35. PubMed ID: 10395192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Investigational PPAR-gamma agonists for the treatment of Type 2 diabetes.
    Savkur RS; Miller AR
    Expert Opin Investig Drugs; 2006 Jul; 15(7):763-78. PubMed ID: 16787140
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic potential of Takeda-G-protein-receptor-5 (TGR5) agonists. Hope or hype?
    Hodge RJ; Nunez DJ
    Diabetes Obes Metab; 2016 May; 18(5):439-43. PubMed ID: 26818602
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro preclinical lead optimisation technologies (PLOTs) in pharmaceutical development.
    Atterwill CK; Wing MG
    Toxicol Lett; 2002 Feb; 127(1-3):143-51. PubMed ID: 12052652
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibody World Summit 2007--SRI's Sixth Annual Meeting. Discovery & development/manufacturing & processing. 16-17 July 2007, New Brunswick, NJ, USA.
    Morrow KJ
    IDrugs; 2007 Oct; 10(10):686-9. PubMed ID: 17899482
    [No Abstract]   [Full Text] [Related]  

  • 15. Metabolic Diseases Drug Discovery World Summit--SRI conference. Diabetes and obesity. 28-29 July 2003 San Diego, CA, USA.
    Xu J
    IDrugs; 2003 Sep; 6(9):850-1. PubMed ID: 14565170
    [No Abstract]   [Full Text] [Related]  

  • 16. American Chemical Society - 240th national meeting - chemistry for preventing and combating disease: part 1.
    Burt J
    IDrugs; 2010 Oct; 13(10):669-72. PubMed ID: 20878582
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of Drug-Induced Hepatotoxicity Using Long-Term Stable Primary Hepatic 3D Spheroid Cultures in Chemically Defined Conditions.
    Vorrink SU; Zhou Y; Ingelman-Sundberg M; Lauschke VM
    Toxicol Sci; 2018 Jun; 163(2):655-665. PubMed ID: 29590495
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo pharmacological disease models for psoriasis and atopic dermatitis in drug discovery.
    Petersen TK
    Basic Clin Pharmacol Toxicol; 2006 Aug; 99(2):104-15. PubMed ID: 16918710
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Techniques: magnetic resonance imaging of the lung provides potential for non-invasive preclinical evaluation of drugs.
    Beckmann N; Tigani B; Mazzoni L; Fozard JR
    Trends Pharmacol Sci; 2003 Oct; 24(10):550-4. PubMed ID: 14559408
    [No Abstract]   [Full Text] [Related]  

  • 20. [Diabetes in 2015: constantly increasing, but with enlarged therapeutics options].
    Jornayvaz FR; Philippe J
    Rev Med Suisse; 2015 Jun; 11(477):1219-20. PubMed ID: 26211280
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.